<DOC>
	<DOCNO>NCT01670357</DOCNO>
	<brief_summary>This study determine efficacy safety 3 % 5 % DA-6034 eye drop compare placebo dry eye syndrome .</brief_summary>
	<brief_title>Phase II Study DA-6034 Eye Drops Dry Eye Syndrome</brief_title>
	<detailed_description>Eligible subject randomly assign receive 3 % DA-6034 , 5 % DA-6034 Placebo . This study conduct 6 week ( Run-in Period 2 week + Treatment Period 4 week ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Age≥20 2 . Dry eye symptom ( irritation , foreign body sensation , burning , mucus discharge , blurring , itching , photophobia , tird heavy feeling , pain ) 6 month 3 . Fluorescein corneal stain score ≥ 4 Schirmer test I ≤ 7mm eye 4 . Corrected vision ≥ 0.2 eye 5 . Have give write , inform consent 1 . Ocular disorder may confound interpretation study result 2 . Current treatment glaucoma IOP 25mmHg 3 . Ocular surgery history within 1 year 4 . Other malignancy history uncontrolled severe disease within 5 year 5 . Use systemic immunosuppressive therapy within 3 month 6 . Use opthalmic cyclosporin , opthalmic steroid within 4 week 7 . Received investigational drug within 4 week 8 . Subjects willing wear contact lenses study participation 9 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dry Eye Syndrome</keyword>
</DOC>